C Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“Brand NEW!: Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, just launched an ‘ACGME NST Advanced Myeloma Fellowship‘!
July 1, 2026, is the start date for this 1-year Advanced Fellowship, which is a FULL-TIME position at the Division of Myeloma and Sylvester Myeloma Institute, University of Miami, Sylvester Comprehensive Cancer Center.
The perfect candidate for this new job is a physician (who completed fellowships in hematology or hematology/oncology) with an interest in cutting-edge clinical care, translational science, modern treatment strategies, teamwork, and/or drug development and novel ideas.
We hope to hear from you soon!
Sylvester Comprehensive Cancer Center is the only NCI-designated cancer center in South Florida. Our catchment area is over 6.4 million people. The Division of Myeloma and Myeloma Research Institute provides world-class care to a large number of myeloma patients in Miami, across the U.S., and internationally. Our clinical trials portfolio is extensive, focusing on Phase 1 and Phase 2 clinical trials. We bring all the latest anti-myeloma drugs to our patients. Our world-class computational discovery research laboratory, as well as our world-class epigenetic research wet laboratory, are leading many innovative research studies, and we collaborate with other major centers worldwide.
Florida has the highest number of newly diagnosed multiple myeloma patients among the 50 states in the U.S. Over 10% of all newly diagnosed patients in the U.S. are diagnosed in Florida. With Miami being the largest city in the state, we are committed to providing world-class care for large numbers of patients within our catchment area. We also see a large number of international multiple myeloma patients and patients from other states across the U.S. Ultimately, we are seeking to develop curative strategies for multiple myeloma.”
More posts featuring C Ola Landgren on OncoDaily.